OpenIcon research & analysis

Changes Coming

As of June 2023, I am transitioning this site to a new purpose. No particular deadline for the new site as it depends on the timing of other events. Thanks for visiting.

Seeking Alpha articles by William P. Meyers


Agenus Readies Comeback with Impressive Botensilimab Data [March 21, 2023, Seeking Alpha]

Biogen Should Resume Strong Growth with Zuranolone Approval [March 7, 2023 at Seeking Alpha]

GlycoMimetics Could Surge [November 16, 2022] at Seeking Alpha

Eagle Bulk Shipping Dividend Sustainability [, 2022] at Seeking Alpha

Illunina Needs Grail, But May Lose It [, 2022] at Seeking Alpha

Microchip Technology Looks to Expand [, 2022] at Seeking Alpha

Bristol Myers Squibb: Growth Plans and Q2 2022 Results [July 29, 2022] at Seeking Alpha

Agios Pharmaceuticals A Buy On Coming Revenue Ramp [July 26, 2022 at Seeking Alpha]

MiNK Therapeutics a Bargain for Cell Therapies [June 23, 2022 at Seeking Alpha]

Biogen: Beyond The Doom And Gloom [March 7, 2022 at Seeking Alpha]

Walgreens Aims For Rapid Growth [October 19, 2021]

Seagen Stock Is A Buy For Its Pipeline Value [September 15, 2021]

Bristol Myers Squibb Q2 2021 Shows Strenth And Value [July 29, 2021] at Seeking Alpha

Biogen's Case for Aduhelm [July 27, 2021 at Seeking Alpha]

Intuitive Surgical has a Good Q2 [July 22, 2021 @ Seeking Alpha]

Inovio Has 4 Sources Of Potential Value [June 2, 2021, Seeking Alpha]

Ionis: Price Slump Is An Opportunity To Buy The Pipeline [June 22, 2021, Seeking Alpha]

Agenus/Bristol Myers Squibb Deal Makes for a Strong Buy [May 28, 2021, Seeking Alpha]

Acceleron: Neutral On Stock Price Gains [April 5, 2021, Seeking Alpha]

Epizyme Comeback Is Likely, Price Makes It A Buy by William Meyers [March 32, 2020 @ Seeking Alpha]